ILTAR, U. Et Al. 2023. Clinical Outcomes of CNS Lymphoma Treated with Ibrutinib-Based Therapy: A Real-Life Multicenter Experience on Off-Label Use of Ibrutinib. UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , vol.33, no.4 , 191-197.

ILTAR, U., SALİM, O., Atas, U., Vural, E., Alhan, F. N., YÜCEL, O. K., ... SÖZEL, H.(2023). Clinical Outcomes of CNS Lymphoma Treated with Ibrutinib-Based Therapy: A Real-Life Multicenter Experience on Off-Label Use of Ibrutinib. UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , vol.33, no.4, 191-197.

ILTAR, UTKU Et Al. "Clinical Outcomes of CNS Lymphoma Treated with Ibrutinib-Based Therapy: A Real-Life Multicenter Experience on Off-Label Use of Ibrutinib," UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , vol.33, no.4, 191-197, 2023

ILTAR, UTKU Et Al. "Clinical Outcomes of CNS Lymphoma Treated with Ibrutinib-Based Therapy: A Real-Life Multicenter Experience on Off-Label Use of Ibrutinib." UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , vol.33, no.4, pp.191-197, 2023

ILTAR, U. Et Al. (2023) . "Clinical Outcomes of CNS Lymphoma Treated with Ibrutinib-Based Therapy: A Real-Life Multicenter Experience on Off-Label Use of Ibrutinib." UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , vol.33, no.4, pp.191-197.

@article{article, author={UTKU ILTAR Et Al. }, title={Clinical Outcomes of CNS Lymphoma Treated with Ibrutinib-Based Therapy: A Real-Life Multicenter Experience on Off-Label Use of Ibrutinib}, journal={UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI}, year=2023, pages={191-197} }